Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 20...

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis Exploratory biomarker analysis provides deeper insights on the immunometabolic biology of psoriasis and potential impact of Taltz (ixekizumab) and Zepbound (tirzepatide) vs. Taltz alone in the TOGETHER-PsO study in adults with psoriasis and obesity INDIANAPOLIS, Oct. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference taking place Oct. 8-11 in Las Vegas.